HUTCHMED (China) Limited

HUTCHMED (China) Limited, listed on Nasdaq under the ticker HCM, is a biopharmaceutical company focused on discovering, developing, and commercializing targeted therapeutics and immunotherapies for cancer and immunological diseases. Its key marketed product is Fruquintinib, an oral inhibitor of vascular endothelial growth factor receptors used to treat colorectal cancer, breast cancer, gastric cancer, and other solid tumors. Another approved drug is Savolitinib, a selective inhibitor of the mesenchymal-epithelial transition receptor for non-small cell lung cancer and papillary renal cell carcinoma. The company also has a pipeline including Surufatinib for neuroendocrine tumors, Sovleplenib for immune thrombocytopenic purpura, and several early-stage candidates like HMPL-760 for lymphomas and HMPL-506 for acute myeloid leukemia. HUTCHMED collaborates with partners such as AstraZeneca to develop and commercialize its therapies globally.

HUTCHMED (China) Limited is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol HCM. Its shares trade in US Dollars (USD). The company is headquartered in Hong Kong and operates primarily in Hong Kong, the United States, and other global markets. As a US-listed company, its financial reporting is in USD, making it accessible to international investors.

HUTCHMED (China) Limited operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This means the company is involved in the research, development, and production of specialized pharmaceutical products, particularly targeted therapies and immunotherapies for cancer and immunological diseases. Unlike broad-based generic drug manufacturers, HUTCHMED focuses on innovative, specialty drugs that address specific medical conditions, such as colorectal cancer, lung cancer, and immune disorders.

HUTCHMED (China) Limited is headquartered in Hong Kong, with operations spanning Hong Kong, the United States, and other global markets. The company serves patients primarily in the US and Asia, leveraging its collaboration with AstraZeneca and other partners to commercialize its drugs internationally. Its products target cancers and immunological diseases prevalent in both Western and Asian populations, such as colorectal cancer, lung cancer, and immune thrombocytopenic purpura.

HUTCHMED (China) Limited's portfolio includes both marketed drugs and pipeline candidates. Its approved products are Fruquintinib, an oral VEGF receptor inhibitor for colorectal cancer and other solid tumors, and Savolitinib, a MET inhibitor for non-small cell lung cancer and papillary renal cell carcinoma. The company also markets Surufatinib for neuroendocrine tumors. In late-stage development are Sovleplenib for immune thrombocytopenic purpura and warm autoimmune hemolytic anemia, Tazemetostat for epithelioid sarcoma and follicular lymphoma, Fanregratinib for intrahepatic cholangiocarcinoma, and Ranosidenib for acute myeloid leukemia. Early-stage candidates include HMPL-760 for lymphomas and HMPL-506 for mixed-lineage leukemia-rearranged acute myeloid leukemia.